Menu Search
Equities

Corvus Pharmaceuticals Inc

C17:BER

Corvus Pharmaceuticals Inc

Actions
  • Price (EUR)8.37
  • Today's Change0.000 / 0.00%
  • Shares traded46.00
  • 1 Year change+580.49%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

  • Revenue in USD (TTM)0.00
  • Net income in USD-22.62m
  • Incorporated2014
  • Employees28.00
  • Location
    Corvus Pharmaceuticals Inc863 Mitten Rd Ste 102BURLINGAME 94010-1311United StatesUSA
  • Phone+1 (650) 900-4520
  • Fax+1 (302) 655-5049
  • Websitehttps://www.corvuspharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.